心肌灌注SPECT后冠状动脉血运重建的生存获益:缺血的作用
在47,894例接受SPECT-MPI的稳定缺血性心脏病患者中,7,973例左心室缺血≥5%,其中1,837例在SPECT-MPI后60天内行早期血运重建。中重度缺血(≥10%)患者早期血运重建较药物治疗全因死亡、死亡+心肌梗死及MACE风险更低,且在他汀优化治疗基础上仍有额外获益;轻度缺血(5%-9%)患者血运重建未改善生存或无心肌梗死生存,且MACE风险更高。
要点
- 中重度缺血(≥10%)患者早期血运重建较药物治疗死亡风险更低,调整后HR 0.67(95%CI 0.50-0.90,P=.008)。
- 轻度缺血(5%-9%)患者血运重建未改善生存或无心肌梗死生存,MACE风险更高,调整后HR 1.30(95%CI 1.12-1.52,P<.001)。
- 在他汀优化治疗亚组中,血运重建仍与更低的死亡风险相关,调整后HR 0.51(95%CI 0.30-0.86,P=.012)。
核心结论
- 与药物治疗相比,中重度缺血患者行血运重建与死亡、死亡+心肌梗死及MACE风险降低相关,且在他汀优化治疗基础上仍有额外获益。
- 轻度缺血患者行血运重建与更高的MACE风险相关,由晚期血运重建驱动,对死亡和死亡+心肌梗死无影响。
研究设计与样本
- 研究纳入47,894例接受SPECT-MPI的稳定缺血性心脏病患者,其中7,973例左心室缺血≥5%。
- 7,973例中1,837例在SPECT-MPI后60天内行早期血运重建,其余为药物治疗亚组。
- 随访期4.04±1.86年,评估了他汀治疗强度与依从性。
主要发现
- 中重度缺血(≥10%)患者早期血运重建组与药物治疗组比较:死亡率1.42%/年 vs 3.12%/年,调整后HR 0.67(95%CI 0.50-0.90,P=.008)。
- 中重度缺血患者死亡+心肌梗死调整后HR 0.69(95%CI 0.55-0.88,P=.003),MACE调整后HR 0.80(95%CI 0.69-0.92,P=.003)。
- 他汀优化治疗亚组中血运重建组与药物治疗组比较:死亡率1.04%/年 vs 2.36%/年,调整后HR 0.51(95%CI 0.30-0.86,P=.012)。
- 轻度缺血(5%-9%)患者血运重建组与药物治疗组比较:MACE率8.86%/年 vs 7.67%/年,调整后HR 1.30(95%CI 1.12-1.52,P<.001)。
关键数值与推荐
- 中重度缺血定义为左心室缺血≥10%。
- 轻度缺血定义为左心室缺血5%-9%。
- 早期血运重建定义为SPECT-MPI后≤60天行血运重建。
- 晚期血运重建定义为SPECT-MPI后>60天行血运重建,为MACE的组成部分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival benefit of revascularization over medical therapy (MT) in patients with stable ischemic heart disease (SIHD) is uncertain. We evaluated the prognostic effects of revascularization in patients with SIHD undergoing single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI). METHODS: Of 47,894 patients, 7973 had ischemia ≥ 5% of the left ventricle. Of these, 1837 underwent early revascularization (≤ 60 days after SPECT-MPI). The rest were MT subgroup. Follow-up period was 4.04 ± 1.86 years. Statin therapy intensity and adherence were assessed. Outcomes were all-cause mortality, death + non-fatal myocardial infarction (MI), and MACE [major adverse cardiac event = death + MI + late revascularization (> 60 days after SPECT-MPI)]. RESULTS: Among patients with moderate-severe ischemia (≥ 10%), death rate was lower in early revascularization compared to MT subgroup (1.42%/year vs 3.12%/year, adjusted hazard ratio (HR) 0.67 (95% CI 0.50-0.90, P = .008). Death + MI and MACE rates were also lower, adjusted HR 0.69 (0.55-0.88, P = .003) and 0.80 (0.69-0.92, P = .003). Revascularization was beneficial in optimal statin therapy subgroup (death rate 1.04%/year vs 2.36%/year, adjusted HR 0.51 (0.30-0.86, P = .012). In mild ischemia (5%-9%), revascularization did not improve survival or MI-free survival, and was associated with higher MACE rate (8.86%/year vs 7.67%/year, adjusted HR 1.30 (1.12-1.52, P < .001). CONCLUSION: Compared to MT, revascularization was associated with reduced risk of death, death + MI, and MACE in patients with moderate-severe ischemia, incremental over optimal statin therapy. In mild ischemia, revascularization was associated with higher risk of MACE, driven by late revascularization, with no impact on death and death + MI.
引用
- Sharir T, Hollander I, Hemo B, et al. Survival benefit of coronary revascularization after myocardial perfusion SPECT: The role of ischemia. J Nucl Cardiol. 2019. PMID: 31823328. doi:10.1007/s12350-019-01932-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。